These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 6314887)

  • 1. Pharmacokinetics of ceftizoxime in patients undergoing continuous ambulatory peritoneal dialysis.
    Burgess ED; Blair AD
    Antimicrob Agents Chemother; 1983 Aug; 24(2):237-9. PubMed ID: 6314887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of intravenous ceftizoxime in patients on continuous ambulatory peritoneal dialysis.
    Johnson CA; Zimmerman SW; Bayer W; Craig WA
    Clin Nephrol; 1985 Mar; 23(3):120-4. PubMed ID: 3857136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceftizoxime elimination kinetics in continuous ambulatory peritoneal dialysis.
    Gross ML; Somani P; Ribner BS; Raeader R; Freimer EH; Higgins JT
    Clin Pharmacol Ther; 1983 Nov; 34(5):673-80. PubMed ID: 6313276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of intravenous and intraperitoneal cefotaxime in chronic ambulatory peritoneal dialysis.
    Albin HC; Demotes-Mainard FM; Bouchet JL; Vincon GA; Martin-Dupont C
    Clin Pharmacol Ther; 1985 Sep; 38(3):285-9. PubMed ID: 4028623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disposition kinetics of cefamandole during continuous ambulatory peritoneal dialysis.
    Bliss M; Mayersohn M; Arnold T; Logan J; Michael UF; Jones W
    Antimicrob Agents Chemother; 1986 Apr; 29(4):649-53. PubMed ID: 3707113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disposition of cefotaxime and desacetyl cefotaxime during continuous ambulatory peritoneal dialysis.
    Heim KL; Halstenson CE; Comty CM; Affrime MB; Matzke GR
    Antimicrob Agents Chemother; 1986 Jul; 30(1):15-9. PubMed ID: 3752976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cefmenoxime kinetics during continuous ambulatory peritoneal dialysis.
    Sica DA; Polk RE; Kerkering TM; Patterson P; Baggett J
    Eur J Clin Pharmacol; 1986; 30(6):713-7. PubMed ID: 3464435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of ceftizoxime in subjects with various degrees of renal function.
    Kowalsky SF; Echols RM; Venezia AR; Andrews EA
    Antimicrob Agents Chemother; 1983 Aug; 24(2):151-5. PubMed ID: 6314884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elimination kinetics of ceftizoxime in humans with and without renal insufficiency.
    Ohkawa M; Okasho A; Sugata T; Kuroda K
    Antimicrob Agents Chemother; 1982 Aug; 22(2):308-11. PubMed ID: 6100425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Absorption of ceftizoxime from peritoneal dialysate and its pharmacokinetics in chronic kidney failure patients].
    Gao S; Li P; Liu GL; Wang SX; Chui RL; Yang JP
    Zhongguo Yao Li Xue Bao; 1992 Jul; 13(4):377-80. PubMed ID: 1456067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of vancomycin in patients undergoing continuous ambulatory peritoneal dialysis.
    Blevins RD; Halstenson CE; Salem NG; Matzke GR
    Antimicrob Agents Chemother; 1984 May; 25(5):603-6. PubMed ID: 6732227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of cefotaxime in patients undergoing haemodialysis and continuous ambulatory peritoneal dialysis.
    Hasegawa H; Imada A; Horiuchi A; Nishii Y; Fukushima M; Kurokawa E
    J Antimicrob Chemother; 1984 Sep; 14 Suppl B():135-42. PubMed ID: 6094432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of hemodialysis and peritoneal dialysis on aztreonam pharmacokinetics.
    Gerig JS; Bolton ND; Swabb EA; Scheld WM; Bolton WK
    Kidney Int; 1984 Sep; 26(3):308-18. PubMed ID: 6542606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of ornidazole in patients with renal insufficiency; influence of haemodialysis and peritoneal dialysis.
    Merdjan H; Baumelou A; Diquet B; Chick O; Singlas E
    Br J Clin Pharmacol; 1985 Feb; 19(2):211-7. PubMed ID: 3986079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug therapy in patients undergoing peritoneal dialysis. Clinical pharmacokinetic considerations.
    Paton TW; Cornish WR; Manuel MA; Hardy BG
    Clin Pharmacokinet; 1985; 10(5):404-25. PubMed ID: 3899455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic studies of cefoxitin in continuous ambulatory peritoneal dialysis.
    Arvidsson A; Alván G; Tranaeus A; Malmborg AS
    Eur J Clin Pharmacol; 1985; 28(3):333-7. PubMed ID: 4007038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of intravenous and intraperitoneal ceftriaxone in chronic ambulatory peritoneal dialysis.
    Albin H; Ragnaud JM; Demotes-Mainard F; Vinçon G; Couzineau M; Wone C
    Eur J Clin Pharmacol; 1986; 31(4):479-83. PubMed ID: 3816928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ceftizoxime: a beta-lactamase-stable, broad-spectrum cephalosporin. Pharmacokinetics, adverse effects and clinical use.
    Neu HC
    Pharmacotherapy; 1984; 4(2):47-60. PubMed ID: 6326062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quinidine pharmacokinetics in continuous ambulatory peritoneal dialysis.
    Chin TW; Pancorbo S; Comty C
    Clin Exp Dial Apheresis; 1981; 5(4):391-7. PubMed ID: 7341025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of intravenous and intraperitoneal fosfomycin in continuous ambulatory peritoneal dialysis.
    Bouchet JL; Albin H; Quentin C; de Barbeyrac B; Vinçon G; Martin-Dupont P; Potaux L; Aparicio M
    Clin Nephrol; 1988 Jan; 29(1):35-40. PubMed ID: 3383462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.